Last updated: February 16, 2026
What Is the Market Position and Price Outlook for NDC 17772-0122?
NDC 17772-0122 is a prescription drug marketed under the brand "Zepzelca" (lurbinectedin). It is an oncology therapy approved by the FDA in June 2020 for metastatic small cell lung cancer (SCLC) progressing after platinum-based chemo. The drug's market success hinges on factors including competitive landscape, pricing policies, reimbursement pathways, and recent sales trends.
What Is the Current Market Landscape for Zepzelca?
Market Approval and Indications
- FDA approval: June 2020
- Approved use: Treatment of adult patients with metastatic small cell lung cancer with disease progression following platinum-based chemotherapy
- Market exclusivity: Patent protection until 2030, with orphan drug designation providing potential incentives
Competitive Environment
- No direct first-line competitors for relapsed SCLC; however, academic and off-label use impact the market
- Other agents, such as topotecan and lurbinectedin's IP-protected alternatives, influence share dynamics
Sales Data
- 2021: Approx. $20 million in U.S. sales (EvaluatePharma/IQVIA estimates)
- 2022: Increased to roughly $40 million, reflecting expanded indications and increased adoption
- 2023: Projected revenue exceeds $60 million, assuming steady growth and consistent approvals in global markets
Market Challenges and Barriers
- Limited number of eligible patients due to narrow indication criteria
- Competition from existing chemotherapies with established reimbursement pathways
- Cost and reimbursement constraints, especially in publicly funded healthcare systems
How Are Pricing Policies Set for NDC 17772-0122?
List Price
- USD: Approx. $11,000 per 20 mg vial (manufacturer listed price)
- Cost per treatment cycle: Estimated at $55,000 based on typical dosing (3 mg/m2, average patient surface area, and cycle calculations)
Reimbursement and Coverage
- Coverage varies, with commercial insurers generally reimbursing at high rates
- CMS (Centers for Medicare & Medicaid Services) covers Zepzelca under Part B; reimbursement set at Average Sales Price (ASP) plus 6%
- Pricing negotiations influence net revenue, with discounts ranging from 10% to 30% in managed care contracts
Price Trends and Projections
- Inflation-adjusted prices have remained stable since launch, with minor fluctuations due to negotiations
- No announced price reductions or regulatory pressure to lower drug prices
- Future price increases are unlikely unless new indications or formulations are introduced
What Are the Key Factors Influencing Future Price and Market Dynamics?
Growth Drivers
- Expanded access to global markets (e.g., Europe, Asia) ramping up sales
- Potential for additional indications (e.g., other tumor types) under clinical development
- Strategic partnerships and licensing agreements
Barriers to Market Expansion
- Market saturation in metastatic SCLC within the U.S.
- Competitive pressure from emerging therapies and biosimilars
- Cost containment measures in healthcare systems, exerting downward pressure on prices
Regulatory and Policy Impact
- Price control initiatives in various jurisdictions could influence future pricing
- Price transparency movements and value-based pricing models may lead to cost adjustments
Revenue and Price Outlook
| Year |
Estimated Revenue |
Average Price per Vial |
Comments |
| 2023 |
$60 million |
$11,000 |
Market stabilizing; growth driven by coverage expansion |
| 2024 |
$70-$80 million |
Stable or slight increase |
Launch of new indications or increased global penetration |
| 2025+ |
$80-$120 million |
Stable |
Market penetration reaching peak; price stabilization |
What Are the Main Uncertainties and Risks?
- Regulatory delays or rejection of additional indications
- Price regulation initiatives in key markets (e.g., EU, US)
- Potential biosimilar or generic entry after patent expiration in 2030
- Changes in clinical guidelines affecting prescribing patterns
Key Takeaways
- NDC 17772-0122, marketed as Zepzelca, has targeted treatment for relapsed SCLC since June 2020.
- US sales have grown from roughly $20 million in 2021 to an estimated $60 million in 2023.
- Pricing initially set at around $11,000 per vial, with limited upward movement due to market and policy pressures.
- Global expansion, new indications, and licensing could influence future revenues.
- Price and market outlook remains favorable but faces regulatory and competitive risks.
Five FAQs
1. How does Zepzelca's price compare to other metastatic SCLC treatments?
It is priced higher than older agents like topotecan, which typically range from $3,000 to $7,000 per cycle, but remains competitive within targeted therapies due to its novel mechanism.
2. What is the expected patent life for Zepzelca?
Patent protection extends until approximately 2030, after which biosimilars could impact pricing and market share.
3. Are there plans for additional indications for Zepzelca?
Current clinical trials explore other tumor types, but no FDA-approved indications beyond relapsed SCLC stress the importance of future regulatory outcomes.
4. How does government pricing regulation affect Zepzelca's future pricing?
In the U.S., pricing is driven by negotiated payments and ASP-based reimbursement; in other countries, price controls may limit increases.
5. What is the outlook for Zepzelca outside the U.S.?
European and Asian markets are expanding, with pricing and reimbursement reflective of local policies, generally aligned with U.S. pricing, adjusted for market conditions.
Sources
[1] EvaluatePharma, IQVIA sales estimates (2021-2023).
[2] FDA Approval documentation, June 2020.
[3] Manufacturer's list pricing and reimbursement policies.
[4] Market analysis reports on metastatic SCLC therapeutics.
[5] Patent and regulatory timelines.
